Published: 2018-06-25

A comparative study of the clinical efficacy and safety of timolol 0.5% and travoprost 0.004% eye drops in primary open angle glaucoma

Shweta M. Bakkewar, Saleem B. Tamboli, Vivek M. Sahasthrabudhe


Background: Raised intraocular pressure (IOP) is a strong risk factor for development of glaucoma. If the condition is detected early enough it is possible to arrest the development or slow the progress with medication that lowers IOP. Travoprost is a newer prostaglandin analogue lowers IOP by facilitating outflow of aqueous humor.

Methods: This was a prospective, randomized, open labelled, parallel group study, in which sixty cases of newly diagnosed primary open angle glaucoma (POAG) were included. After baseline clinical evaluation 30 subjects of glaucoma were treated with timolol 0.5% eye drop while another 30 subjects were given travoprost 0.004% eye drop and followed for 1 month to see IOP lowering efficacy of the two drugs. Statistical analysis was done using Open Epi 2.3 version for paired t test and unpaired t test.

Results: In subjects treated with timolol eye drop mean reduction of IOP from baseline to week 4 was by 6.6mmHg while that of travoprost treated subjects was by 8.07mmHg. There was significant reduction in mean IOP of study subjects in travoprost group as compared to timolol group (P<0.05).

Conclusions: Both timolol 0.5% and travoprost 0.004% eye drops are effective in reducing intra ocular pressure in POAG. On comparison travoprost was found to be statistically superior to timolol in lowering IOP in patients with POAG.


Primary open angle glaucoma, Timolol, Travoprost

Full Text:



Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-7.

Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmol. 2014 Nov 30;121(11):2081-90.

Verma R, Khanna P, Prinja S, Rajput M, Arora V. The National Programme for Control of Blindness in India. Australasian medical J. 2011;4(1):1-3.

Saxena R, Singh D, Vashist P. Glaucoma: An emerging peril. Indian J community medicine: official publication of Indian Association Preventive Social Medicine. 2013 Jul;38(3):135-7.

Jaffrey D, Henderer and Cristopher J Rapiono. Ocular Pharmacology. In: Laurence L, Brunton Bruce A Chabner, Bjorn C Knollmann. Goodmannand Gilman’s The Pharmacological basis of Therapeutics. 12th ed. China: McGraw-Hillcompanies;2011:1773-1802.

Kersey T, Clement CI, Bloom P, Cordeiro MF. New trends in glaucoma risk, diagnosis and management. Ind J Med Res. 2013 Apr 1;137(4):659-68.

Mehani R, Gupta S, Yadav MV, Shukla SD. A Comparative study on safety and efficacy of travoprost and brimonidine/timolol fixed combination in patients of primary open angle glaucoma. Int J Basic Clinical Pharmacol. 2015;4:976-80.

Suzuki Jr ER, Suzuki CL. Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations. Clinical ophthalmology (Auckland, NZ). 2010;4:1165-71.

Khan F, Rehman M, Ilyas O, Tahir MZ, Ahmad I. Comparison of intraocular pressure lowering effect of travoprost and timolol/dorzolamidecombination in primary open angle glaucoma. Pak J Ophthalmol. 2015 Oct;31(4):197.

Babić N, Andreić V, Miljković A, Grković D, Jovanović P. Comparison of the efficacy and safety of the fixed combination travoprost/timolol and dorzolamide/timolol in patients with primary open angle glaucoma and ocular hypertension. Srp Arh Celok Lek. 2013 Jul 1;141(7-8):441-6.

Kammer JA, Katzman B, Ackerman SL, Hollander DA. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study. British J Ophthalmol. 2010 Jan 1;94(1):74-9.

Giuffre I. Comparative evaluation of the efficacy of the bimatoprost 0.03%, brimonidine 0.2%, brinzolamide 1%, dorzolamide 2%, and travoprost 0.004%/timolol 0.5%-fixed combinations in patients affected by open-angle glaucoma. Open J Ophthalmol. 2012 Nov 16;2(04):122.

Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003 May 31;135(5):688-703.

Goldberg I, Cunha-Vaz J, Jakobsen JE, Nordmann JP, Trost E, Sullivan EK. International Travoprost Study Group. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001 Oct 1;10(5):414-22.

Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001 Oct 31;132(4):472-84.

Fellman RL, Sullivan EK, Ratliff M, Silver LH, Whitson JT, Turner FD, et al. Travoprost Study Group. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmol. 2002;109(5):998-1008.

Cheng JW, Xi GL, Wei RL, Cai JP, Li Y. Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis. Current Therapeutic Research. 2009;70(4):335-50.

Deepankar UP, Jain B. To compare the efficacy of different prostaglandins as monotherapy in POAG. J. Evolution Med Dent Sci. 2016;5(66):4713-15.

Mehani R, Yadav VK, Sankadia RK, Ghodki S, Garg T. Comparision of the adverse effects profile of travoprostvsbrimonidine/timolol in patients of primary open angle glaucoma in central Indian population of Bhopal. Inter J Curr Res Review. 2016 Jan 1;8(1):51-4.